- Home
- ATOS vs AIRE Comparison
ATOS vs AIRE Comparison
Compare ATOS & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- AIRE
- Stock Information
- Founded
- ATOS 2009
- AIRE 2021
- Country
- ATOS United States
- AIRE United States
- Employees
- ATOS N/A
- AIRE N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- AIRE
- Sector
- ATOS Health Care
- AIRE
- Exchange
- ATOS Nasdaq
- AIRE Nasdaq
- Market Cap
- ATOS 96.8M
- AIRE 86.1M
- IPO Year
- ATOS 2012
- AIRE N/A
- Fundamental
- Price
- ATOS $0.89
- AIRE $0.60
- Analyst Decision
- ATOS Strong Buy
- AIRE Strong Buy
- Analyst Count
- ATOS 3
- AIRE 1
- Target Price
- ATOS $7.13
- AIRE $3.00
- AVG Volume (30 Days)
- ATOS 611.2K
- AIRE 110.1K
- Earning Date
- ATOS 05-13-2025
- AIRE 05-27-2025
- Dividend Yield
- ATOS N/A
- AIRE N/A
- EPS Growth
- ATOS N/A
- AIRE N/A
- EPS
- ATOS N/A
- AIRE N/A
- Revenue
- ATOS N/A
- AIRE $948,420.00
- Revenue This Year
- ATOS N/A
- AIRE $206.83
- Revenue Next Year
- ATOS N/A
- AIRE $158.08
- P/E Ratio
- ATOS N/A
- AIRE N/A
- Revenue Growth
- ATOS N/A
- AIRE 419.58
- 52 Week Low
- ATOS $0.55
- AIRE $0.52
- 52 Week High
- ATOS $1.74
- AIRE $4.49
- Technical
- Relative Strength Index (RSI)
- ATOS 64.44
- AIRE 33.66
- Support Level
- ATOS $0.78
- AIRE $0.56
- Resistance Level
- ATOS $0.92
- AIRE $0.66
- Average True Range (ATR)
- ATOS 0.06
- AIRE 0.03
- MACD
- ATOS 0.01
- AIRE 0.02
- Stochastic Oscillator
- ATOS 81.82
- AIRE 42.39
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About AIRE reAlpha Tech Corp.
ReAlpha Tech Corp is a real estate technology company that develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability; and has an app for investment into the properties that it purchased aimed at retail investors. The company's reportable segments are; Platform Services, which derives key revenue, and the Rental business segment.